Work

Pembrolizumab in pediatric participants with relapsed or refractory microsatellite instability-high solid tumors: Results from the phase 1/2 KEYNOTE-051 trial.

Year: 2025

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2025.43.16_suppl.10040

Authors: Alberto S. Pappo, Hyoung Jin Kang, Margaret E. Macy, Steven G. DuBois, Tanya Carens Watt, Claudia Rossig, Luciana Vinti, Robert J. Hayashi, Kumudu Pathiraja, Rohini Singh, Alexander Gozman, Birgit Geoerger

Institutions: St. Jude Children's Research Hospital, Seoul National University Hospital, Seoul National University Children's Hospital, Children's Hospital Colorado, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, The University of Texas Southwestern Medical Center, University Hospital Münster, Bambino Gesù Children's Hospital, Washington University in St. Louis, Merck & Co., Inc., Rahway, NJ, USA (United States), Institut Gustave Roussy

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4410804754

Cites:

Cited by: 2

Related to: 10